Julian Bryson

Avata Biosciences, formerly Sapient Therapeutics Ltd., is a clinical-stage biopharmaceutical company with a mission to improve the lives of patients living with neurological disease with synthetic cannabinoids and a novel formulation process designed to address larger patient populations.